Since the packaging of the two Roter products that are the subject of this website does not indicate the PAC (pro-anthocyanidins) content, little can be said about their efficacy. Their so-called patented Cranberry-Active® appears to be identical to an effect of cranberries as such, and has possibly been introduced to enable it to be registered as a medical device, as the clinical research requirements for their authorisation are less stringent.7 Although the use of cranberry products may offer certain advantages compared to that of antibiotics, evidence for their efficacy has been limited and not convincing. And the fact that the PAC content is not indicated makes it even more difficult to judge the possible efficacy of these products, so it seems unwise to spend money on them.


  1. Jepson RG, et al. Cranberries for treating urinary tract infections. Cochrane Database Syst Rev 1998: CD001322.
  2. Jepson RG, et al. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev 2012: CD001321.
  3. Pinxteren B van, et al. NHG-Standaard ’Urineweginfecties’ (derde herziening). Huisarts Wet 2013; 56: 270-280.
  4. Schmidt DR, et al. An examination of the anti-adherence activity of cranberry juice on urinary and nonurinary bacterial isolates. Microbios 1988; 55: 173–181.
  5. Prior RL, et al. Multi-laboratory validation of a standard method for quantifying proanthocyanidins in cranberry powders. J Sci Food Agric 2010; 90: 1473–1478.
  6. Howell AB, et al. Dosage effect on uropathogenic Escherichia coli anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: a multicentric randomized double blind study. BMC Infectious Diseases 2010; 10: 94.
  7. EU-richtlijn medische hulpmiddelen 93-42-EEG [document op het internet]. Via: https://www.nen.nl/NEN-Shop/Vakgebieden/Medische-Hulpmiddelen/Wetgeving-medische-hulpmiddelen/Richtlijn-medische-hulpmiddelen-9342EEG-1.htm.

*The literature refers to the Dutch text


  • mw drs M.A.E. Nieuwhof